MaxCyte MXCT 深 沪
已收盘 11-07 16:00:00 美东时间
1.44
-0.030
-2.04%
华盛通- 最 高1.47
- 今 开1.45
- 成交量 74.99万股
- 最 低 1.385
- 昨 收 1.47
- 总市值 1.54亿
- 52周最高 5.20
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 1.26
- 委 比 54.33%
- 总股本 1.07亿
- 历史最高 17.44
- 量 比 0.98
- 振 幅 5.78%
- 历史最低 1.26
- 每 手 1
- 风险率 1.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MaxCyte Reports Preliminary Q3 Revenue of $6.8M And Reiterates Its 2025 Revenue Guidance
MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its preliminary results for the third quarter ended September 30, 2025 and reiterated its 2025 revenue g
11-05 21:24
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
MaxCyte Signs Strategic Platform License Agreement With Moonlight Bio To Advance T Cell Therapy Development
MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today
10-06 20:07
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte Inc. has signed a Strategic Platform License agreement with Moonlight Bio to support the development of T cell therapies using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. Moonlight Bio aims to improve outcomes for solid tumor treatments. MaxCyte will receive licensing fees and program-related revenue.
10-06 12:05
MaxCyte Announces Major Workforce Reduction Plan
MaxCyte ( ($MXCT) ) has shared an announcement. On September 22, 2025, MaxCyte,...
09-23 04:59
MaxCyte announces 34% workforce reduction to cut costs
MaxCyte (NASDAQ:MXCT) is implementing a restructuring plan that includes a 34% reduction in its global workforce, including EOR personnel. The move is aimed at cutting operating expenses, streamlining...
09-23 04:36
MaxCyte Restructures Operations, Reduces Global Workforce By 34% To Unlock ~$13.6M In Annual Savings
MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today
09-23 04:33
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
MaxCyte, Inc. announced a restructuring to align resources with strategic priorities, reducing its global workforce by approximately 34%, resulting in $13.6 million annual savings. This aims to reduce expenses, streamline operations, and move toward profitability. The company expects 2025 core revenue to be flat or down 10% from 2024, with $5 million in SPL program revenue and year-end cash of at least $155 million. CEO Maher Masoud emphasized th...
09-22 20:30
A Preview Of Bionano Genomics's Earnings
Bionano Genomics (NASDAQ:BNGO) is set to give its latest quarterly earnings rep...
08-14 02:02
MaxCyte Chief Commercial Officer Departs Amid Severance Agreement
An announcement from MaxCyte ( ($MXCT) ) is now available. On August 11, 2025, ...
08-12 05:08
